{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:33:33Z","timestamp":1787646813869,"version":"build-2736575974"},"reference-count":71,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"World Association for Infectious Diseases and Immunological Disorders","award":["WAidid-2026-03"],"award-info":[{"award-number":["WAidid-2026-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Dengue has expanded rapidly beyond traditional tropical and subtropical regions, driven by climate change, urbanization, population mobility, and the spread of competent Aedes vectors. Vaccination is an increasingly important component of dengue prevention, but development has been complicated by four viral serotypes, antibody-dependent enhancement, variable baseline serostatus, and the need for balanced and durable tetravalent immunity. Methods: We conducted a narrative review of PubMed\/MEDLINE, Google Scholar, ClinicalTrials.gov, and relevant public health and regulatory sources. Evidence on dengue epidemiology, immunopathogenesis, licensed vaccines, advanced candidates, efficacy, immunogenicity, safety, durability, and implementation was critically evaluated. Priority was given to randomized trials, long-term follow-up studies, regulatory assessments, and surveillance data. Evidence was synthesized descriptively without formal meta-analysis or risk-of-bias assessment. Results: CYD-TDV was the first licensed dengue vaccine but is restricted to individuals with documented previous infection because seronegative recipients may experience an increased risk of severe dengue. TAK-003 has demonstrated overall efficacy against virologically confirmed dengue and dengue-related hospitalization in both baseline-seropositive and baseline-seronegative populations. However, protection is heterogeneous by serotype, and evidence remains limited or uncertain for some serotype-by-serostatus strata. Butantan-DV offers a promising single-dose strategy, but broader use requires additional long-term safety, effectiveness, and serotype-specific data. Inactivated, DNA, viral-vectored, virus-like particle, and mRNA vaccines remain investigational. Conclusions: Dengue vaccination should be integrated with surveillance, vector control, clinical preparedness, and risk communication. Population-based vaccination is most appropriate in high-transmission settings, whereas selective, risk-based strategies are preferable in temperate regions. Continued pharmacovigilance and effectiveness monitoring are essential to guide safe and equitable implementation.<\/jats:p>","DOI":"10.3390\/vaccines14090729","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:49:34Z","timestamp":1787582974000},"page":"729","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dengue Vaccines in a Changing Epidemiological Landscape: Current Evidence, Unresolved Challenges, and Public Health Considerations"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-2837","authenticated-orcid":false,"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-5568","authenticated-orcid":false,"given":"Nicola","family":"Principi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 Degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue","volume":"393","author":"Ooi","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-023-41017-y","article-title":"Projecting the future incidence and burden of dengue in Southeast Asia","volume":"14","author":"Gibb","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"obaf011","DOI":"10.1093\/iob\/obaf011","article-title":"Climate Change and Vector-Borne Disease Transmission: The Role of Insect Behavioral and Physiological Adaptations","volume":"7","author":"Abbasi","year":"2025","journal-title":"Integr. Org. Biol."},{"key":"ref_6","unstructured":"World Health Organization (2025). Dengue: Global situation, surveillance and progress\u20142024 update. Wkly. Epidemiol. Rec. Relev. \u00c9pid\u00e9miologique Hebd., 52, 665\u2013678."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.15585\/mmwr.mm7518a1","article-title":"Increase in travel-associated and locally acquired dengue cases\u2014United States, 2024","volume":"75","author":"Kiplagat","year":"2026","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_8","unstructured":"European Centre for Disease Prevention and Control (2026, July 05). Surveillance and Updates on Dengue, Available online: https:\/\/www.ecdc.europa.eu\/en\/dengue."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101758","DOI":"10.1016\/j.lanepe.2026.101758","article-title":"Preparing Europe for recurrent autochthonous dengue transmission: Public health implications and preparedness priorities","volume":"66","author":"Ippolito","year":"2026","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1038\/s41467-025-61109-1","article-title":"Risk assessment and perspectives of local transmission of chikungunya and dengue in Italy, a European forerunner","volume":"16","author":"Menegale","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_11","unstructured":"Istituto Superiore di Sanit\u00e0 (2026, July 05). Sorveglianza Nazionale Delle Arbovirosi: Aggiornamento Dengue 2024\u20132026. Available online: https:\/\/www.epicentro.iss.it\/febbre-dengue\/2025."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(07)61687-0","article-title":"Dengue","volume":"370","author":"Halstead","year":"2007","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wilder-Smith, A., Cherian, T., and Hombach, J. (2025). Dengue vaccine development and deployment into routine immunization. Vaccines, 13.","DOI":"10.3390\/vaccines13050483"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri3916","article-title":"New insights into the immunopathology and control of dengue virus infection","volume":"15","author":"Screaton","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wegman, A.D., Fang, H., Rothman, A.L., Thomas, S.J., Endy, T.P., McCracken, M.K., Currier, J.R., Friberg, H., Gromowski, G.D., and Waickman, A.T. (2021). Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.777672"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wegman, A.D., Waldran, M.J., Bahr, L.E., Lu, J.Q., Baxter, K.E., Thomas, S.J., and Waickman, A.T. (2023). DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection. PLoS Pathog., 19.","DOI":"10.1101\/2023.04.01.535210"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tsai, W.Y., Pierson, T.C., Wrammert, J., Dejnirattisai, W., Jumnainsong, A., Mongkolsapaya, J., Screaton, G., Crowe, J.E., and Wang, W.K. (2025). Mature dengue virus particles inactivated by a non-ionic detergent retain quaternary neutralizing epitopes and induce potent neu-tralizing antibodies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1626823"},{"key":"ref_21","first-page":"7061","article-title":"Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope","volume":"6","author":"Rouvinski","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Weiskopf, D., and Sette, A. (2014). T-cell immunity to infection with dengue virus in humans. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00093"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/imm.12681","article-title":"CD4+ and CD8+ T-cell immunity to dengue\u2014Lessons for the study of Zika virus","volume":"150","author":"Rivino","year":"2017","journal-title":"Immunology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0065-3527(03)59009-1","article-title":"Microevolution and virulence of dengue viruses","volume":"59","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_25","first-page":"300","article-title":"Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"328","author":"Guirakhoo","year":"2004","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1080\/21645515.2017.1333211","article-title":"Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 years after vaccination","volume":"13","author":"Vigne","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e65131","DOI":"10.7554\/eLife.65131","article-title":"Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data","volume":"10","author":"Laydon","year":"2021","journal-title":"eLife"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/cid\/ciab288","article-title":"Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America","volume":"73","author":"Forrat","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","unstructured":"World Health Organization (2018). Meeting of the Strategic Advisory Group of Experts on Immunization. Wkly. Epidemiol. Rec., 93, 329\u2013343."},{"key":"ref_35","unstructured":"U.S. Food and Drug Administration (2026, July 05). Dengvaxia, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/dengvaxia."},{"key":"ref_36","unstructured":"European Medicines Agency (2026, July 05). Dengvaxia, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dengvaxia."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S1473-3099(20)30722-2","article-title":"Optimising dengue pre-vaccination screening","volume":"21","author":"Peeling","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Fongwen, N., Wilder-Smith, A., Gubler, D.J., Ooi, E.E., Salvana, E.M.T., de Lamballerie, X., Olliaro, P.L., and Peeling, R.W. (2021). Target product profile for a dengue pre-vaccination screening test. PLoS Neglected Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009557"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20190234","DOI":"10.1098\/rsif.2019.0234","article-title":"Serostatus testing and dengue vaccine cost-benefit thresholds","volume":"16","author":"Pearson","year":"2019","journal-title":"J. R. Soc. Interface"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/infdis\/jiv258","article-title":"CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate","volume":"212","author":"Chu","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: A randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2018.05.028","article-title":"A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: A randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2\u201317 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"Tricou","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year Efficacy and Safety of Takeda\u2019s Dengue Vaccine Candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_50","unstructured":"Takeda (2026, July 05). New Phase 3 Data Show Takeda\u2019s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization. Available online: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2025\/dengue-vaccine\/."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Shen, J., Kharitonova, E., Tytula, A., Zawieja, J., Aballea, S., Biswal, S., Sharma, M., Rungmaitree, S., Sruamsiri, R., and Wallace, D. (2025). Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand. PLoS Med., 22.","DOI":"10.1371\/journal.pmed.1004789"},{"key":"ref_53","unstructured":"Government of India, Ministry of Health and Family Welfare (2026, August 23). CDSCO Approves India\u2019s First Dengue Vaccine, Strengthening National Dengue Prevention Efforts. Press Information Bureau, Available online: https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=2286883&lang=2&reg=48&utm_source=chatgpt.com."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/vim.2006.19.10","article-title":"Development of a live attenuated dengue virus vaccine using reverse genetics","volume":"19","author":"Blaney","year":"2006","journal-title":"Viral Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD\u2122 vaccine?","volume":"15","author":"Whitehead","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_56","unstructured":"GDAC (2026, July 05). Butantan\u2019s Dengue Vaccine Has 79.6% Efficacy, Partial Results from 2-Year Follow-Up Show, Available online: https:\/\/gdac-dengue.org\/news-events\/butantans-dengue-vaccine-has-79-6-efficacy-partial-results-from-2-year-follow-up\/."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, Attenuated, Tetravalent Butantan\u2013Dengue Vaccine in Children and Adults","volume":"390","author":"Cintra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1473-3099(24)00376-1","article-title":"Efficacy and safety of Butantan-DV through extended follow-up: Phase 3 trial in Brazil","volume":"24","author":"Nogueira","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/s41591-026-04255-3","article-title":"Long-term efficacy and safety of the single-dose tetravalent Butantan-DV vaccine: 5-year follow-up of a phase 3 trial","volume":"32","author":"Moreira","year":"2026","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/S0140-6736(26)01239-0","article-title":"Brazil suspends Butantan dengue virus vaccinations","volume":"407","author":"Alves","year":"2026","journal-title":"Lancet"},{"key":"ref_61","unstructured":"GOV (2026, July 05). BR Anvisa Will Establish a Panel of Experts to Deepen the Epidemiological Investigation About the Butantan-DV Vaccine, Available online: https:\/\/www.gov.br\/anvisa\/en\/updates\/anvisa-will-establish-a-panel-of-experts-to-deepen-the-epidemiological-investigation-about-the-butantan-dv-vaccine."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4269\/ajtmh.14-0819","article-title":"Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial","volume":"93","author":"Martinez","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/S0264-410X(99)00570-8","article-title":"Dengue virus type 1 DNA vaccine induces protective immune responses in mice and monkeys","volume":"18","author":"Raviprakash","year":"2000","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1016\/j.vaccine.2011.07.019","article-title":"Development of dengue DNA vaccines","volume":"29","author":"Danko","year":"2011","journal-title":"Vaccine"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Anumanthan, G., Sahay, B., and Mergia, A. (2025). Current Dengue Virus Vaccine Developments and Future Directions. Viruses, 17.","DOI":"10.3390\/v17020212"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Parra-Gonz\u00e1lez, M., N\u00e1jera-Maldonado, L., Peralta-Cuevas, E., Gutierrez-Onofre, A.J., Garcia-Atutxa, I., and Villanueva-Flores, F. (2025). Overcoming dengue vaccine challenges through next-generation virus-like particle immunization strategies. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1614805"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"127216","DOI":"10.1016\/j.vaccine.2025.127216","article-title":"Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue","volume":"57","author":"Kumari","year":"2025","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Pinzon Burgos, E.F., Camacho Ortega, S., Atkinson, B., Chua, J.V., and Heredia, A. (2026). Opportunities and Challenges of mRNA and VLP Technologies for Pan-Flavivirus Vaccine Development: Focus on Conserved Quaternary Epitope Conformations. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27021081"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/729\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:15:50Z","timestamp":1787645750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":71,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090729"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090729","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}